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It has recently been stated that a database is an essential tool in the management of CF. The purpose of this work is to create a specific
database allowing optimal performance of storage, search and retrieval functions on patients with CF. A specific database was developed
using a Windev licence, for application via Microsoft supported platforms or Intranet system. The database allows real-time point of care data
management of medical, investigational and administrative data. It is currently being used in the 6 Belgian reference centres. It represents a
useful tool for gathering information on routine clinical and lab data, bacteriology, treatments, complications and specific outcomes for
clinical and research purposes. The ongoing evolution of the database includes enhancements toward research data orientation including
comparison of patient data between different centres and completeness of the National CF registry questionnaire. A complimentary copy of
the software can be provided to multidisciplinary accredited CF centres worldwide upon request.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Database; Registry1. Introduction
Cystic fibrosis (CF) is the most common autosomal
recessive inherited disease with fatal outcome in Caucasian
populations. CF disease involves pulmonary, gastrointesti-
nal, nutritional, psychological, urological and obstetric
complications [1]. Despite impressive advances in under-
standing the molecular basis of the disease, these have not
been translated into better clinical care (other than neonatal
screening) and life expectancy is still limited in CF.
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doi:10.1016/j.jcf.2006.07.002are responsible for the progressive loss of lung function
which is the main cause of morbidity and mortality in CF.
Over the last decade, a generic approach to track the progress
of this chronic disease and to allow improving life ex-
pectancy and quality of life has been established by the
emergence of a multidisciplinary group of health care pro-
fessionals including clinicians and specialist paramedical
staff such as nurses, physiotherapists, nutritionists, social
workers, psychologists, pharmacists and clinical biologists
[2,3]. A recent European consensus for standards of care for
patients with CF has summarized functions of each member
of the CF team and has stated that database is an essential
tool in the management of CF and that every patient with CF
should be part of a local and national database [4]. The work
described here was aimed at creating a specific clinical and
administrative database [5] which provides support of patient
data management for multidisciplinary CF teams. The
developed software should facilitate optimizing performanceed by Elsevier B.V. All rights reserved.
Fig. 1. Data management diagram used in the CFdbase software.
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and contribute to fulfil the needs of the datasheet completion
of the national registry questionnaire.
2. Technical issues and requirements of the CF database
The CF database (CFdbase) is a databank system built for
matching specific needs of a multidisciplinary and accredited
CF team, towhich computer specialists and databasemanagers
have advantageously joined favouring the development of the
software infrastructure. It was developed using Windev as a
general programming language for applications via Microsoft
supported platforms or Intranet system. By integrating a set of
tools within the data system, the software can be expanded
from a single-user workstation to large multiuser networks.
The database is open to interoperability with Windows-based
applications andAccess supports. The CFdbase recommended
system requirements are listed in Table 1. The program runs in
a multilingual– English, Dutch and French– application.
3. Working with the CF database
3.1. Data input and processing
Fig. 1 outlines the data management diagram from a new
patient data up to the creation from further exploitation of the
generated databank. As a data collection tool, the CFdbase
allows a real-time data entry of multiple administrative,
clinical and investigational information. In our centre, 154
patients were entered into the CFdbase.
The main functions of the data capture patient file and
different aspects of the record are illustrated in the sub-
sections of Fig. 2. Completion of all fields of the patient file
occurs prospectively by the physician during outpatient
visits or hospitalizations and it takes less than 2 min. In order
to illustrate the multiple functionalities of the CFdbase while
recording or editing individual patient data, a real anon-
ymised patient from our CF centre was selected. The patient
is a 20-year-old girl homozygous for the ΔF508 mutation.
She is attending our CF centre since diagnosis at 1 month
when she first presented with chronic respiratory symptoms
and failure to thrive (Fig. 2.7). Last name, first name, date of
birth and sex represent essential data required for recording aTable 1
CFdbase recommended system requirements
Operating system: Windows XP/2000/NT4 are the preferred platforms.
Windows 95 and 98 are also supported. Administrator rights has to be
enabled for Windows XP
Hardware: Intel® Pentium®-compatible processor (PII 300Mhz minimum)
Memory: 64MB (128MB RAM preferred)
2MB DirectX 6.1 compatible graphics card or above support
DirectX 6.1 compatible sound card or above support (optional)
CD-Rom drive (speed 4×) or above support
SVGA monitor (800×600) or above support
Keyboard and mouse
Up to 50MB of available hard-disk spacenew patient in the databank system (Fig. 2.1). Data capture
occurs using integrated operational modules accessed by
differentiated buttons. Each button opens windows (Fig. 2.2)
containing data classified into different sections, namely
medical and administrative data, outpatient visits and hos-
pitalizations, therapies, complications, lab tests and proce-
dures including those examining the eventuality of allergic
broncho-pulmonary aspergillosis (ABPA), bacteriologic data
and antibiotic therapy information. A separate button is
available to export anonymous data to the national registry.
In the medical datasheet section, button presentations (Fig.
2.5) display modules including initial disease profile at the
time of CF diagnosis or circumstances leading to diagnosis;
phenotype–genotype information including pancreatic status
and details of specific CFTR mutations; complementary
diagnostic tests performed such as sweat test and nasal
potential difference; family history details; evaluation of
patient and/or family decision process regarding listing for
organ transplantation; enlisted circumstances (cardiac, respi-
ratory, hepatic, trauma, suicide or other causes linked to cancer,
to an organ transplantation or unknown causes) in which
patients die; tobacco habits and atopy history; and the presence
of chronic colonization by P. aeruginosa and recent isolation
of Burkholderia cepacia. Data processing of these two latter
features generates particular alarm signs (Fig. 2.6). Other
generated alarm icons include those for allergy to medications,
Fig. 2. Datasheet for input, update, search and retrieval functions from an actual CF patient registered with the CFdbase software. 1— Patient identification;
2— Toolbars allowing to access multiple clinical, investigational and administrative patient data modules; 3— Toolbar allowing to select separate modules to be
used by the paramedical staff (physiotherapist, nurse, social worker, nutritionist, psychologist, varia); 4— Toolbar allowing to access a single screen displaying
summarized information of the patient including basic medical and historical data, phenotype–genotype, longitudinal graphical representation of weight, BMI
(body mass index), lung function and bacteriology data drawn as a 5-year span table; 5—Multiple thumbnail presentations to access modules for collection data,
as indicated; 6— Area allocated for alarm icons, such as that indicating the presence of chronic colonization by Pseudomonas aeruginosa; 7— Formatted data-
field definitions for easy checking-off; 8— Blank field for additional free-text annotation.
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to increase completeness, accuracy and validity, data input
process is usually entered by checking-off formatted data-field
definitions (Fig. 2.7). Additional blank fields are provided for
free-text annotation, as appropriate (Fig. 2.8).
Absolute anthropometric and spirometric values, including
weight (in Kg), height (in cm), FVC and FEV1 (in L), entered
at each clinic outpatient visit or throughout hospitalizations,
are converted in percentiles, percentage of normal values for
age and sex [6,7], and Z scores [8] and are therefore auto-
matically integrated in the databank. For sequential assessment
of nutritional status, body mass index (BMI) and percentage
weight for height, calculated for children [9], are converted in
percentile charts and Z scores. Tracking of developmental data
with respect to the NCHS percentiles is drawn in the familiar
graphical growth chart format. Graphical and table output of
anthropometry and spirometry data are easily accessed via the
longitudinal data button (Fig. 2.2).
3.2. Data update
All individual recording files can easily be edited for
adding or changing data. Application updates, as new re-cording files, are carried out in real-time in routine clinical
practice by the physician during outpatient visits or through-
out hospitalizations. A warning validation rule requests
confirmation while adding, changing or withdrawing data.
3.3. Data search
Database search capability for individual patients and for
collective data is facilitated by graphical, spreadsheets and
tables output generated by the software. Assessing a button
presentation (Fig. 2.4) provides a one-screen summary
(Fig. 3) of the most relevant clinical data including age at
diagnosis, genotype, pancreatic status, sweat chloride and
nasal potential difference results, and graphical illustrations
of growth, BMI chart in Z score, lung function curves and
microbiology data for the 5 last years. The latter allows to
easily applying Lee's classification of Pseudomonas infec-
tions [10] for individual patients.
For illustrating collective data capability of the software,
a survey report of spirometric (Fig. 4) and microbiological
(Fig. 5) data fromCFpatients regularly receiving full-time care
at our centre at the end of the year 2005 was downloaded.
Spirometric data are processed for the whole, paediatric and
Fig. 3. One-screen summary of clinical and laboratory data of an actual CF patient registeredwith the CFdbase software. BMI is expressed in Z score according to age.
FEV1 is expressed as percentage of predicted values for age and sex according to Knudson et al [6]. Weight is expressed as percentage of ideal weight. Results from
cultures performed in every outpatient visit are drawn as a 5-year span table in which each successive month is defined.
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severity of the lung disease [11]. Analysis of global frequency
and prevalence of respiratory pathogens is determined
annually taking into account results of cultures entered in
every outpatient visit. As illustrated in Fig. 5, the prevalence
of each listed pathogens, including mucoid and non-mucoid
P. aeruginosa strains, appears clearly in the report.
3.4. Data retrieval
Data retrieval from the CFdbase meet clinical routine
practice, epidemiological research purposes and the needs of
the national CF registry that documents diagnosis and annual
follow-up evaluations of CF patients who are seen at national
accredited centres. Thanks to interoperability with Microsoft
Office software components, individual or collective data
can be easily printed or exported as spreadsheets, tables or
graphs. Exporting data to an Excel format file is used for
transferring data to the national registry.As originally developed in the UK CF database [12], for
completion of the national CF registry, a unique clinic-based
PIN number is automatically generated for each patient by a
standard hashing algorithm that retains personal identifying
details such as the patient date of birth and sex, his(her)
position amongst siblings and his(her) mother's date of birth.
The PIN code allows patient anonymity and identifies the
patient within the database. The PIN code is kept private
even the patient is seen in another CF clinics. After written
informed consent has been obtained, patient data are annu-
ally assembled to complete the database protocol and for
merging with the national CF dataset.
4. Discussion
We developed an advanced, specialised, yet simple to use,
CF database system allowing day-to-day patient data man-
agement in routine clinical practice during outpatient visits or
throughout hospitalizations. The software contains a help file
Fig. 4. Collective spirometric data of 118 CF patients attending our centre at the end of 2005. Data are processed for the whole, paediatric and adult population,
also assigned according to the degree of severity of the lung disease [11].
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ric references used. It was built for answering specific needs of
multidisciplinary and accredited CF teams [13–16] following
the recommendations of the recent European consensus [4],
and for contributing to solve eventual tensions between local
clinicians and the needs of the national registry. New re-
cording, update, display and retrieval functions of clinical,
investigational and administrative patient data are tightly
integrated for an unlimited number of registered patients. Real-
time point of care data entry does not need to be previously
recorded on paper forms. For resourced CF centres, this
represents a time saving advantage as others in clinical routine
practice which also advantageously favours homogeneity in
data acquisition (Table 2). Indeed, electronic data sources have
proven to be a great help in achieving complete and validated
data, in reducing data variability and in minimizing handoffs,
human errors or bias potential that enter into retrospective data
collection [17]. By integrating a set of tools within the data
system, the database can be utilized from a single-user work-
station to large multiuser networks. A transition period for
transferring historical data from paper-based files to electronic
database is required.
The software brings advanced search capability of pro-
ducing individual and longitudinal patient reports that can help
the clinician to provide feedback to each patient about their
growth, lung function, nutritional or infection status. Thesegraphical outputs can be shared with the patient or his(her)
family during outpatient visits, in the hope that this could
improve their adherence to follow-up. Moreover, this dataset
can facilitate epidemiological, cross-sectional and longitudinal
research. Ready access to longitudinal analysis of individual
patients is provided by graphical, worksheet and table output
generation including growth charts, drawn in absolute values
or Z scores, and plots of lung function according to age. An
original graphical display of the software is that of the
microbiological data, which plots results of respiratory
cultures performed at each outpatient visit, every 3-month
interval, over a 5-year selected period. This allows to easily
using Lee's classification [10] for defining the prevalence of
P. aeruginosa colonization. In the absence of agreement on
what is best practice, percentage weight for height was chosen
for assessment of nutritional status in children though its
reliability has been questioned because of the wide inter and
intraexaminer variation of the measure [9].
At a national level, the database has been pivotal in making
measurable improvements in the quality of data and in
favouring reporting completeness of the national registry ques-
tionnaire, which is quite similar to that of the CF Foundation
Patient Registry. The database developed in 2003 is regularly
running in Belgian CF reference centres facilitating national
registry of 865 CF patients [18]. It is now widely recognized
that CF patient registry serves as a vital resource to access the
Fig. 5. Collective microbiological data of 141 CF patients attending our centre at the end of 2005. Y-axis indicates the number of infected patients for the listed
pathogens. Corresponding percentages are indicated in the top of columns.
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[12]. Assessment of electronically available patient information
is of paramount importance for improving data accuracy while
reducing the needs for manual retrospective review of medical
records for the national CF registry records. The overall trend
will be that of the fields with missing values in the national
registry questionnaire, which has yet to achieve 100% com-Table 2
Main advantages of electronic version of CFdatabase over paper-based files
For individual data
Easy accessibility to administrative and medical data
Standardization of data acquisition
Rapid visualization of recent or historical clinical data
Summary and graphical representation of longitudinal outcomes (spirometry,
anthropometry, bacteriology)
Easy application of Lee's classification [10]
For collective data
Annual (or specified period) review of main patient parameters
Warning list including patients requiring particular follow-up
Possibility of exportation of data to research and analysis
Registry
Automatic generation of majority of data
Few risk of misencoding or losing datapleteness, will disappear and all CF patients, remaining linked
and confidential, will be a part of the national registry.
Finally, creating and having a database should not be an end
goal but rather a source of valid data and a means for
generating information bywhich to readily assess care process,
performance, and outcomes quality. As CF is a genetic disease
common acrossmany nations that derive their population from
Caucasians and as the software was designed to cope with a
multi-system disease such as CF and to integrate information
about various aspects of the disease, we agree the CF database
we developed could be attractive to be used in other CF centres
worldwide. The use of a specific standardised tool for data
gathering could facilitate the identification of the influences of
the environment and of differences in therapies on the pro-
gression of CF disease. Moreover, as proposed for stan-
dardisation of national registry reports [19,20], it could favour
comparisons between countries of patient data [21].
In conclusion, our Belgium CF database provides an on-
going record of disease progression and a useful tool for
gathering information on routine clinical and lab data, bac-
teriology, treatments, complications and specific outcomes for
clinical routine and research purposes. The ongoing evolution
of the database includes enhancements toward research data
orientation including comparison of patient data between
different centres and completeness of the National CF registry
193T. Leal et al. / Journal of Cystic Fibrosis 6 (2007) 187–193questionnaire. A complimentary copy of the software can be
provided free of charge to multidisciplinary accredited CF
centres worldwide upon request.References
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